Back to search results

Care in Multiple Sclerosis (MS) Study

This observational study, called "Care in Multiple Sclerosis (MS)," aims to understand how childhood experiences and social factors affect people living with relapsing-remitting multiple sclerosis (RRMS). Researchers will develop ways to assess childhood adversity, then study its impact on MS outcomes. They will also explore environmental and social factors that affect the quality of life for minority MS patients. The study is looking for 300 participants, aged 18 and older, who have RRMS. A significant portion of participants (70%) will be from groups historically underrepresented in MS research, including Black, Hispanic, or poverty-impacted individuals. The study measures the severity of MS at the beginning of the study.

Study design
This is an observational study with an unclear status, planning to enroll 300 participants.
What's involved
If you participate in Aim 2, you will have two visits that include a research blood draw and an MRI scan.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07011914

Care in Multiple Sclerosis (MS)

Recruiting
Not specifiedAges 18+Observational
NYU Langone Health
~300 participants
Updated 2026-05-05 on ClinicalTrials.gov

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Severity of MS
Measured over Baseline

Conditions

Multiple Sclerosis

Explore related trials

Relapsing-Remitting Multiple Sclerosis

NCT07011914

Where you'd take part

This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Baylor College of Medicine

    Houston, Texasno site contact published

    Recruiting

  • Cleveland Clinic

    Cleveland, Ohiono site contact published

    Recruiting

  • Massachusetts General Hospital

    Boston, Massachusettsno site contact published

    Recruiting

  • University of Alabama at Birmingham

    Birmingham, Alabamano site contact published

    Recruiting

  • University of California, San Francisco

    San Francisco, Californiano site contact published

    Recruiting

  • University of Colorado Denver

    Aurora, Coloradono site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Lauren Krupp, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Who to contact

Taj Adams
[email protected]
646-501-7528
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

aged ≥18-29 years
diagnosis of RRMS (Fulfill international criteria for relapsing remitting (RRMS))
70% self-identifying as a Black, Hispanic, or poverty-impacted (up to 138% of the federal poverty level) individual,and
fluent in English or Spanish.
aged ≥18-29 years
diagnosis of RRMS (Fulfill international criteria for relapsing remitting (RRMS))
70% self-identifying as a Black, Hispanic, or poverty impacted, and
fluent reading in English or Spanish
Pediatric onset MS (MS onset before age 18 and age at time of enrollment is 18-25) OR adult-onset MS (MS onset at age 18 or older and age at time of enrollment is 19-29)
Disease duration below 8 years
completed at least 80% of study data in the cross-sectional study/Aim 2.
a total of 70% must self-identify as Black, Hispanic, or meet criteria for poverty impacted.
interviews will be evenly split between participants with high (top quartile) and low (bottom quartile) of PROMIS-10 scores.

Exclusion

Primary or Secondary Progressive MS
Inability to consent.
MS relapse within 30 days prior to study entry
Other major neurologic or psychiatric illness

What this trial measures

  • Severity of MSBaseline

    Severity of MS will be measured by MRI FLAIR lesion volume among Aim 2 participants.